Amicus Therapeutics, Inc. (NASDAQ:FOLD) major shareholder Perceptive Advisors Llc purchased 335,827 shares of Amicus Therapeutics stock in a transaction dated Monday, March 5th. The shares were bought at an average price of $13.56 per share, with a total value of $4,553,814.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of Amicus Therapeutics, Inc. (FOLD) traded up $0.01 during trading hours on Wednesday, reaching $15.17. The company’s stock had a trading volume of 7,937,537 shares, compared to its average volume of 3,710,000. The stock has a market capitalization of $2,520.00, a PE ratio of -18.06 and a beta of 1.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.60 and a quick ratio of 5.53. Amicus Therapeutics, Inc. has a fifty-two week low of $6.41 and a fifty-two week high of $17.40.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.11). The firm had revenue of $14.73 million during the quarter, compared to analysts’ expectations of $14.50 million. Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. equities analysts forecast that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current year.
Large investors have recently made changes to their positions in the business. American International Group Inc. boosted its position in Amicus Therapeutics by 23.1% in the third quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock worth $1,653,000 after purchasing an additional 20,597 shares during the last quarter. Perceptive Advisors LLC boosted its position in Amicus Therapeutics by 3.4% in the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock worth $269,760,000 after purchasing an additional 591,925 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in Amicus Therapeutics in the fourth quarter worth about $392,000. Sphera Funds Management LTD. boosted its position in Amicus Therapeutics by 5.0% in the third quarter. Sphera Funds Management LTD. now owns 420,000 shares of the biopharmaceutical company’s stock worth $6,334,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Cowen Inc. boosted its position in Amicus Therapeutics by 1,436.4% in the third quarter. Cowen Inc. now owns 147,000 shares of the biopharmaceutical company’s stock worth $2,217,000 after purchasing an additional 158,000 shares during the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.